Karyopharm Therapeutics (KPTI) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lantern Pharma (LTRN) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 81.9% versus a loss of 89.6%. Over five years, LTRN leads with a -91.7% price change compared with -99.3% for KPTI. Karyopharm Therapeutics is the larger company by market cap ($13.7 million vs $12.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPTI | LTRN |
|---|---|---|
| Share price | $0.605 | $0.8127 |
| Market cap | $13.72M | $12.14M |
| 1-day change | +0.83% | -2.08% |
| YTD return | -91.78% | -72.61% |
| 1-year return | -89.60% | -81.92% |
| 5-year return | -99.28% | -91.71% |
| EPS (TTM) | $-14.33 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $4.68 |
| 52-week low | $0.5652 | $0.7603 |
| Distance from 52-week high | -94.49% | -82.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1098.35% | +2053.32% |
| Average volume | 1.71M | 180.42K |
| Shares outstanding | 22.68M | 14.94M |
| Employees | 228 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
KPTI vs LTRN FAQ
Which is bigger, Karyopharm Therapeutics or Lantern Pharma?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.72M compared with $12.14M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, KPTI or LTRN?
LTRN returned -81.92% over the past 12 months, compared with -89.60% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Karyopharm Therapeutics and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.